The present invention relates to an isolated CD31+ cell derived from adipose-derived regenerative cells (ADRC's), for use as a medicament. The invention also relates to compositions comprising such cells. In addition, the invention relates to methods for screening for the regenerative capacity of a population of adipose-derived regenerative cells (ADRC's).
Original languageEnglish
Patent numberWO2019193052 (A1)
Filing date10/10/2019
Priority date04/04/2018
Priority numberDKPA201870194A
Publication statusPublished - 10. Oct 2019


Dive into the research topics of 'Stem cells and progenitor cells bearing CD31'. Together they form a unique fingerprint.

Cite this